Let’s measure what matters, together.

Get the latest research on how Folia Health’s Home Reported Outcomes can surface unparalleled patient insights. No email required. Download buttons below!

Want to continue the conversation with the Folia Health team, and see how Folia’s mobile research platform can unlock a new layer in your evidence? Give us your details and we’ll be in touch!

Recent HRO Publications

  • NKF Folia Poster

    Real-time and Short Recall of Flares in PNH, Captured through Longitudinal Home-Reported Outcomes

    Download Poster
  • ASN Folia IgAN poster

    Common vs Frequent: Assessing variable disease presentation in IgAN and C3G, through home-reported outcomes and patient-reported endpoints analyses

    download Poster

  • Exploring burden in rare diseases: examining neuropsychological symptoms, flares, and sleep quality

    download poster

Capture Patient Experience Data Others Can't Reach

High-frequency, longitudinal Home Reported Outcomes (HROs) connect patient quality of life with treatments and symptoms delivering the real-world evidence your strategy needs.

Learn more

Recent Press

Press Releases
Folia Health Launches FSGS PULSE Study to Generate a More Complete Understanding of FSGS Disease Burden and Treatment
Folia Health Launches FSGS PULSE Study to Generate a More Complete Understanding of FSGS Disease Burden and Treatment

BOSTON, August 6, 2026 — Folia Health today announced the launch of the FSGS PULSE Study, a remote observational study designed to generate a more complete understanding of disease burden and treatment impact among people living with focal segmental glomerulosclerosis (FSGS).

Read more →
Folia Health's Comment to FDA on AI-Enabled Early-Phase Clinical Trials
Folia Health's Comment to FDA on AI-Enabled Early-Phase Clinical Trials

Folia Health is pleased to submit a response to the FDA's Request for Information on Docket No. FDA-2026-N-4390, AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program.

We believe the success of this pilot program relies on the richness of the underlying data, which must represent the full impact of a drug candidate on the health status and disease burden of the patient. This is best accomplished by including real-time patient experience data in these programs, grounded in the methodology established by the FDA's PFDD guidance. Our decade of work with biopharma sponsors generating real-time patient-generated evidence reinforces this position.

Read more →
Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers
Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers

BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Folia Health announces the launch of Burden and Real-world Assessment of Caregiver Voice and Experiences in Prader-Willi syndrome (BRAVE-PWS), a fully remote observational study, sponsored by Soleno Therapeutics (NASDAQ: SLNO), designed to better understand the real-world experience of caregivers supporting individuals with Prader-Willi syndrome (PWS)…

Read more →
Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP
Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP

BOSTON, April 7, 2026 (GLOBE NEWSWIRE)-- Folia Health today announced a collaboration with argenx to launch a first-of-its-kind, at-home observational real-world evidence initiative supporting individuals living with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)…

Read more →
Folia Health Expands Its Rare Renal Disease Research with a New C3G Study to Assess Real-World Disease Impact
Folia Health Expands Its Rare Renal Disease Research with a New C3G Study to Assess Real-World Disease Impact

BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Folia Health launches enrollment for an innovative, at-home real-world evidence initiative for individuals with C3 glomerulopathy (C3G). This initiative, conducted in collaboration with Novartis Pharmaceuticals Corporation, aims to directly measure patient-defined burden and evaluate the impact of various treatments on quality of life…

Read more →
book a consultation